### Meet the CHOP Experts

#### SATURDAY, DEC. 7



11 AM
Lindsey A. George, MD
Director of Clinical In Vivo
Gene Therapy



11:15 AM
Janet Kwiatkowski, MD,
MSCE
Director of the Thalassemia
Center




1:30 PM
Alexis Thompson, MD,
MPH
Chief of the Division of
Hematology



3 PM Stephan Grupp, MD, PhD Chief of the Cellular Therapy and Transplant Section

### SUNDAY, DEC. 8



Noon Stephen Hunger, MD Jeffrey E. Perelman Distinguished Chair in Pediatrics Chief, Division of Pediatric Oncology Director, Center for Childhood Cancer Research




12:30 PM
Ben Samelson-Jones,
MD, PhD
Associate Director of Clinical
In Vivo Gene Therapy



2 PM
Michele P. Lambert, MD
Medical Director of the
Special Coagulation
Laboratory

#### MONDAY, DEC. 9



10 AM
Caroline Diorio,
MD, FRCPC, FAAP
Attending physician,
Cancer Center



10:30 AM
David Teachey, MD
Attending physician,
Cancer Center

# Highlighted Presentations SATURDAY, DECEMBER 7

#### 9:30 AM



The Expanding
Landscape of
Treatment for ITP

• • •

Michele P. Lambert, MD

Chair and Speaker

"On the Horizon: Upcoming
New Agents for the
Management of ITP"

9:30 AM



ASH Clinical Practice Guidelines on Pediatric Venous Thromboembolism (VTE)

• • •

Leslie Raffini, MD

Speaker

"Why Revise the Guidelines?"

# Highlighted Presentations SATURDAY, DECEMBER 7

9:45 AM



116 Near Universal National Uptake of Dexrazoxane in the Real-World Setting Associated with Reduced Cardiac ICU Care Requirements in Pediatric Acute Myeloid Leukemia

• • •

Daniel J. Zheng, MD
Presenter

4:30 PM



315 Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children's Oncology Group (COG) Protocols

• • •

David Teachey, MD
Co-Author

# Highlighted Presentations SUNDAY, DECEMBER 8

9:45 AM



512 Durable Clinical
Benefits with
Exagamglogene
Autotemcel for
Transfusion-Dependent
Î<sup>2</sup>-Thalassemia

Stephan Grupp, MD, PhD
Co-Author

12:30 PM



603 Innovative Model for Creation and Use of Co-Developed Pain Management Plans for Patients with Sickle Cell Disease

Alexis Thompson, MD, MPH
Presenter

### Highlighted Presentations SUNDAY, DECEMBER 8

#### 2:05 PM



1 Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children's Oncology Group Study AALL1731

• • •

Stephen Hunger, MD
Co-Author

#### 6 PM



3577 Use of
Fidanacogene
Elaparvovec, a Gene
Therapy Vector, to Deliver
a Stable, Fully Functional
Human Factor IX
Transgene for the
Treatment of Hemophilia
B: A Combined Analysis
of Safety

• • •

Ben Samelson-Jones, MD, PhD

Presenter

## Highlighted Presentations MONDAY, DECEMBER 9

4:30 PM



ASH Research Collaborative
Data Hub Sickle Cell Disease
Network: Accelerating
Research and Collaborative
Clinical Care through
Real-World Evidence
Generation

• • •

Alexis Thompson, MD, MPH Co-Chair and Speaker 5:15 PM



1054 Long-Term Factor
VIII Expression Post
AAV in Adult
Hemophilia a Mice
Demonstrates No
Evidence of Adverse
Liver Health or
Tumorigenesis

• • •

Lindsay A. George, MD

Presenter